Marathon, Under Heavy Fire for Emflaza Pricing, Makes Surprise Deal to Sell Drug for $140M-Plus

Marathon Pharmaceuticals is in plenty of hot water after its brazen $89,000 pricing on the old-turned-new Duchenne muscular dystrophy drug Emflaza—a decades-old product available overseas for $1,000 per year. Now, it’s scored a quick payoff by selling the med to PTC Therapeutics in a deal potentially worth more than $190 million.

Read More

Senate GOP Holdouts Split Into Rival Camps On Obamacare Overhaul

The House is racing to find enough votes for its health-care bill this week, but even if it passes, prospects in the Senate have only darkened.

Read More

Nevada Rep Amodei Not Sold On Republican Health Care Plan

U.S. Rep. Mark Amodei says, if he had to vote Monday, he would likely vote against a Republican plan to reform federal health care laws.

Read More

Sandoval, Other Republican Governors Complain About GOP Health Care Plan

Republican governors complain that a GOP proposal to replace former President Barack Obama's health care law would force millions of lower-income earners off insurance rolls or stick states with the cost of keeping them covered.

Read More

Deciphering CBO’s Estimates On The GOP Health Bill

The Congressional Budget Office is out with its estimate of what effects the Republican health bill, “The American Health Care Act,” would have on the nation’s health care system and how much it would cost the federal government. The GOP plan is designed to partially repeal and replace the Affordable Care Act passed during the Obama administration.

Read More

Companies Behind Health Savings Accounts Could Bank On Big Profits Under GOP Plan

Health savings accounts are poised for a major expansion by Republicans in Washington, D.C., and that could mean millions more customers — and fees — flowing to a handful of companies.

Read More
arrowcaret-downclosefacebook-squarehamburgerinstagram-squarelinkedin-squarepauseplaytwitter-squareyoutube-square